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External Validation of the Risk Assessment Model of the International
Medical Prevention Registry on Venous Thromboembolism (IMPROVE)
for Medical Patients in a Tertiary Health System
David Rosenberg, MD, MPH; Ann Eichorn, MS; Mauricio Alarcon; Lauren McCullagh, MPH; Thomas McGinn, MD, MPH;
Alex C. Spyropoulos, MD

Background-—Hospitalized medical patients are at risk for venous thromboembolism (VTE). Universal application of pharmacological thromboprophylaxis has the potential to place a large number of patients at increased bleeding risk. In this study, we aimed
to externally validate the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) VTE risk assessment
model in a hospitalized general medical population.
Methods and Results-—We identiﬁed medical discharges that met the IMPROVE protocol. Cases were deﬁned as hospital-acquired
VTE and conﬁrmed by diagnostic study within 90 days of index hospitalization; matched controls were also identiﬁed. Risk factors
for VTE were based on the IMPROVE risk assessment model (aged >60 years, prior VTE, intensive care unit or coronary care unit
stay, lower limb paralysis, immobility, known thrombophilia, and cancer) and were measured and assessed. A total of 19 217
patients met the inclusion criteria. The overall VTE event rate was 0.7%. The IMPROVE risk assessment model identiﬁed 2 groups of
the cohort by VTE incidence rate: The low-risk group had a VTE event rate of 0.42 (95% CI 0.31 to 0.53), corresponding to a score
of 0 to 2, and the at-risk group had a VTE event rate of 1.29 (95% CI 1.01 to 1.57), corresponding to a score of ≥3. Low-risk status
for VTE encompassed 68% of the patient cohort. The area under the receiver operating characteristic curve was 0.702, which was
in line with the derivation cohort ﬁndings.
Conclusions-—The IMPROVE VTE risk assessment model validation cohort revealed good discrimination and calibration for both
the overall VTE risk model and the identiﬁcation of low-risk and at-risk medical patient groups, using a risk score of ≥3. More than
two thirds of the entire cohort had a score ≤2. ( J Am Heart Assoc. 2014;3:e001152 doi: 10.1161/JAHA.114.001152)
Key Words: clinical prediction rules • hospitalized medical patients • risk assessment models • thromboprophylaxis • venous
thromboembolism

V

enous thromboembolism (VTE) represents an important
issue in the hospitalized, acutely ill medical patient
population. Estimates from US databases reveal that up to 8
million hospitalized, acutely ill medical patients are at risk
annually for developing VTE.1 The incidence of deep vein
thrombosis has been reported to range from 10% to 26%
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among general medical patients, and 75% of fatal pulmonary
embolisms occur in nonsurgical patient populations.2,3 Recent
evidence suggests that higher rates of VTE prophylaxis in the
absence of formal VTE risk stratiﬁcation may not lead to
reduced VTE rates.4
National quality organizations in the United States have
opted for a group risk assessment and thromboprophylaxis
strategy in the hospitalized medical patient5,6; however,
recent international guideline statements have stressed the
need for individualized VTE risk assessment through the use of
VTE risk assessment models (RAMs) in the acutely ill medical
patient population.5,7 This would allow proper identiﬁcation of
medical patients at risk of VTE and minimize potential harm
from thromboprophylaxis for patients at low risk of VTE.7
Multiple VTE RAMs in the hospitalized, acutely ill medical
patient population have been derived by expert consensus or by
regression analysis to identify patient groups at risk for VTE8–13;
however, the VTE RAMs either have not undergone proper
external validation or have been assessed only in management
or impact analysis studies.9,12 Proper external validation in
Journal of the American Heart Association

1

Validation of IMPROVE VTE RAM

Rosenberg et al

Methods
Medical patients at risk of VTE were identiﬁed as having been
admitted to 1 of 2 tertiary care hospitals during the time
period for which both billing and electronic health record data
were available (December 2009 to April 2013.) Patients had
be aged at least 18 years, have a length of stay of at least
3 days, and be discharged alive. Index admission required a
primary medical diagnosis of acute infection, respiratory
disease, heart failure, cancer, diabetes, pancreatitis, cholecystitis, or inﬂammatory bowel or rheumatic disease (Table
S1). Patients with a secondary obstetric or mental health
diagnosis were excluded (International Classiﬁcation of Diseases, 9th revision [ICD-9] codes 290 to 319 or 630 to 677).
In an attempt to exclude patients with major surgical
procedures, we included only patients whose billing diagnosis-related group was suggestive of medical admission and
excluded those suggestive of a surgical diagnosis. In addition,
patients were excluded from the cohort if they had an
international normalized ratio >1.5 or were receiving a
therapeutic dose of anticoagulant therapy.
We identiﬁed VTE events using ICD-9 codes (415.11,
415.13, 415.19, 451.11, 451.19, 451.81, 453.4, 453.40,
453.41, 453.87, 453.9). If the patient had a VTE ICD-9 code
as a secondary diagnosis present on admission for the index
admission, the patient was excluded from the study. VTE
events were those coded as not present on the index
admission or, for those patients who did not have an event on
the index admission, those coded as present on admission for
their ﬁrst readmission within 90 days following the index
admission. Any readmission during the study period that did
not identify a VTE event and that met the study criteria placed
the patient in the at-risk cohort again.
For a case–control approach to the individual risk factor
analysis, we identiﬁed a sample of non-VTE patients to match
to the cases in a case–control format. Approximately 3
DOI: 10.1161/JAHA.114.001152

controls were identiﬁed for each case, matched by hospital,
admission year, and patient sex. For quality control purposes,
manual review of certain key data was performed. First, each
VTE event identiﬁed by billing data was conﬁrmed by review of
objective testing result (Doppler compression ultrasound of
lower extremity, chest computed tomography angiograms,
and ventilation/perfusion scans). Cases were excluded from
the study if no report could be found or if results were not
consistent with VTE. Second, for all cases and controls, any
operative reports associated with the index admission or
90 days prior were reviewed. Any report identifying a major
surgical procedure resulted in exclusion of the case from the
study. This review was not performed for the noncase
population.
Patient characteristics considered as risk factors for VTE
were those identiﬁed by the IMPROVE VTE RAM study.10
Points were assigned to each of these characteristics
according to the 7-factor IMPROVE model (previous VTE, 3
points; known thrombophilia, 2 points; lower limb paralysis, 2
points; cancer, 2 points; immobilization, 1 point; intensive
care unit or coronary care unit stay, 1 point; aged >60 years,
1 point). For the risk factor of immobility, we used the proxy of
bed rest for >7 days or a hospital length of stay >7 days. For
the risk factor of lower limb paralysis, we used the proxy of
hemiparesis, hemiplegia, paraplegia, or quadriplegia, as
documented in the nursing-assessment ﬂow sheet of motor
response (Table S2).
In the original derivation study of the IMPROVE VTE RAM,
the American College of Chest Physicians (ACCP) threshold
warranting pharmacological thromboprophylaxis was an
IMPROVE score corresponding to a clinical VTE event rate
of at least 1%.10 To perform our validation study of the
IMPROVE VTE RAM, data were extracted from the electronic
health records of close to 20 000 patients to reﬂect each
patient’s risk status during the index admission. Expected VTE
event rates were calculated using the IMPROVE risk score and
for individual risk factors along with their associated 95% CIs.
Given the relatively low event rate, a case–control study was
performed, and odds ratios were calculated for each IMPROVE
VTE risk-score category relative to the lowest risk group. A
logistic regression model was calculated from the case–
control sample to evaluate the predictive ability of the model.
Receiver operating characteristic (ROC) curves were created
to compare the overall diagnostic accuracy of the original
derivation set10 and our validation set. All analyses were
conducted using SAS version 9.3 (SAS Institute Inc).
The procedures used were reviewed and approved as being
in compliance with ethical standards of the responsible
institutional review committee at the home institution of the
authors. All research activities were in compliance with the
World Medical Association Declaration of Helsinki on Ethical
Principles for Medical Research Involving Human Subjects.
Journal of the American Heart Association
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settings and patient populations different from the populations
from which the model was derived ensures the model’s
reproducible accuracy prior to widespread clinical use.14 The
International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) VTE RAM was derived from a large
international registry of 15 156 hospitalized, acutely ill medical
patients.10,15 The RAM consisted of 7 independent VTE risk
factors that were given 1 to 3 points each, depending on their
strength of association with VTE risk.10 These risk factors were
then added to give a ﬁnal composite VTE risk score that
described the individual patient’s VTE risk. Thresholds were
then applied to deﬁne VTE risk groups. The objective of this
study was to externally validate the IMPROVE VTE RAM in a
hospitalized, general medical population as part of a large
academic health system in the United States.
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prior VTE (Table 2). The results were essentially unchanged
when the cases and controls were stratiﬁed into groups that
received VTE prophylaxis, including pharmacological prophylaxis, during hospitalization and those that did not.

Results
A total of 19 217 patients met the inclusion criteria, as shown
in Figure 1. From this group, we identiﬁed 135 cases with a
hospital-acquired VTE event and 404 matched controls
without a hospital-acquired VTE event. Demographics for
these groups are provided in Table 1. The cases were older
(aged 70.78 versus 65.68 years) and had longer hospital
length of stay (12.68 versus 7.48 days) than controls, and a
higher percentage were female (62% versus 53%). A higher
percentage of cases also had multiple VTE risk factors.

Risk Factor Analysis
Of the 7 risk factors identiﬁed in the IMPROVE RAM study, 3
were found to be statistically associated with the risk of VTE
in this population: aged >60 years, diagnosis of cancer, and

Risk Score Analysis
The event rate and odds ratio at each level of IMPROVE risk
score is shown in Table 3. The risk scores were collapsed into
binary VTE risk categories of low risk and at risk, as shown in
Table 4. This approach divides the 2 groups by their VTE
incidence rates: The low-risk group had a VTE event rate of
0.42 (95% CI 0.31 to 0.53), corresponding to an IMPROVE
score of 0 to 2, and the at-risk group had a VTE event rate of
1.29 (95% CI 1.01 to 1.57), corresponding to an IMPROVE
score of ≥3. The odds ratio between the low-risk and at-risk
groups was 3.07 (95% CI 2.17 to 4.33). Further calibration
analysis revealed the ability of the model to distinguish
between incidence rates based on the number of VTE events
at each score level (score 0, 1, 2, 3, 4, 5 to 10) (Table S3).

Figure 1. Deﬁnition study population. DRG indicates diagnosis-related group; ICD-9, International
Classiﬁcation of Diseases, 9th revision; INR, international normalized ratio; LIJMC, Long Island Jewish
Medical Center; LOS, length of stay; NSUH, North Shore University Hospital; VTE, venous thromboembolism.
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This study was exempt from patient consent because the
study was an analysis of a large data set.

Rosenberg et al
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Noncases

VTE Event

Non-VTE
Event

n=19 082

n=135

n=404

Mean

65.7

70.8

66.1

Median

68

73

68

SD

18.3

14.1

17.7

Age, y

Discussion

Sex
Female

53%

62%

62%

Male

47%

38%

38%

Acute infection

39%

26%

39%

Respiratory

21%

19%

19%

Heart failure

14%

7%

15%

Cancer

14%

43%

12%

Diabetes, pancreatitis,
cholecystitis

9%

2%

12%

Inflam bowel disease

3%

2%

3%

Rheumatic disease

0%

0%

0%

Mean

7.48

12.68

7.18

Median

Qualifying illness

Index admission LOS

6

9

6

VTE prophylaxis,
pharmacological
or order for mechanical

49%

49%

45%

Pharmacological VTE
prophylaxis

43%

44%

40%

LOS indicates length of stay; VTE, venous thromboembolism.

Model Discrimination
The ROC curve analysis is shown in Figure 2, in which the
area under the ROC curve is 0.70 in our validation set. The

This study represents one of the largest, multicenter, external
validation studies of a weighted and evidence-derived VTE
RAM in hospitalized, acutely ill medical patients, using the
IMPROVE VTE risk score. The validation population revealed
good discrimination characteristics of the risk score when
compared with the original derivation population.10 The
derivation and validation populations also exhibited concordance of VTE risk distribution across VTE risks scores,
speciﬁcally, in low-risk and at-risk VTE risk score thresholds.
Last, the results of this validation study used 7 evidencederived independent clinical factors in a weighted scoring
system as part of the IMPROVE RAM that can be readily
assessed during the course of hospital admission or hospital
stay in the medically ill patient population.
This external validation study displayed an area under the
ROC curve of 0.70, compared with the area under the ROC
curve of 0.72 seen in the derivation cohort, which revealed
good discrimination characteristics. In addition, as seen in the
original derivation study, the validation study exhibited good
calibration across increasing VTE risk scores, with symptomatic VTE event rates of 0.4% with IMPROVE scores of 0 to 2
(low VTE risk) and symptomatic VTE event rates of >1.0% with
IMPROVE scores of ≥3 (at VTE risk). Importantly, if we
assumed an IMPROVE score of ≥3 as a VTE risk threshold—as
recommended by the ACCP guidelines for warranting pharmacological thromboprophylaxis, given a clinical VTE event
rate of ≥1%—the present study suggested that 66% of the
medically ill validation population would be at low risk of VTE.

Table 2. Risk Factors Associated With the IMPROVE RAM Score

Aged >60 years

VTE Event (n=135)

Non-VTE Event (n=404)

OR (95% CI)

P Value

108 (80.0%)

268 (66.34%)

2.03 (1.27 to 3.25)

0.0028

Prior cancer

76 (56.3%)

116 (28.71%)

3.20 (2.14 to 4.78)

<0.0001

Prior VTE

26 (19.26%)

28 (6.93%)

3.20 (1.80 to 5.69)

<0.0001

ICU/CCU stay

19 (14.07%)

41 (10.15%)

1.45 (0.81 to 2.60)

0.2093

Lower limb paralysis

1 (0.74%)

8 (1.98%)

0.37 (0.05 to 2.98)

0.4618

Immobility

42 (31.11%)

117 (28.96%)

1.11 (0.73 to 1.69)

0.6352

Known thrombophilic state

1 (0.74%)

1 (0.25%)

3.01 (0.19 to 48.41)

0.4385

ICU/CCU indicates intensive care unit or coronary care unit; IMPROVE, International Medical Prevention Registry on Venous Thromboembolism; OR, odds ratio; RAM, risk assessment
model; VTE, venous thromboembolism.

DOI: 10.1161/JAHA.114.001152
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negative and positive predictive values at each level of risk
score are presented in Table 5. The negative predictive value
was 99% across the IMPROVE RAM. The areas under the curve
of the ROC curves did not show appreciable differences
between the derivation and validation sets (derivation set
0.72; validation set 0.70) (Figure S1).

Table 1. Demographics of Study Population

Validation of IMPROVE VTE RAM

Rosenberg et al
ORIGINAL RESEARCH

Table 3. Event Rate and Odds Ratio at Each Level of IMPROVE Risk Score
VTE

No VTE

Score

n=135

n=19 082

Event Rate

OR (95% CI)

0

5

3917

0.13

Reference

1

27

5662

0.47

3.74 (1.44 to 9.71)

2

23

3368

0.68

5.35 (2.03 to 14.09)

3

41

3598

1.13

8.93 (3.52 to 22.62)

4

12

1393

0.85

6.75 (2.37 to 19.19)

5

11

596

1.81

14.46 (5.01 to 41.76)

6

11

369

2.89

23.35 (8.07 to 67.58)

7

4

140

2.78

22.38 (5.95 to 84.25)

≥8

1

39

2.5

20.09 (2.2933 to 175.94)

IMPROVE indicates International Medical Prevention Registry on Venous Thromboembolism; OR, odds ratio; VTE, venous thromboembolism.

Table 4. Risk Scores Expressed as Binary VTE Risk
Score

VTE (n=135)

No VTE (n= 19 082)

Event Rate (95% CI)

OR (95% CI)

0 to 2 (low risk)

55

12 947

0.42 (0.31 to 0.53)

Reference

≥3 (high risk)

80

6135

1.29 (1.01 to 1.57)

3.07 (2.17 to 4.33)

OR indicates odds ratio; VTE, venous thromboembolism.

This ﬁnding is similar to the high proportion of patients with
low VTE risk (66%) seen in the original derivation population.10
Consequently, the present validation study suggests an
IMPROVE VTE risk score of ≥3 as a useful threshold in

predicting an increased risk of VTE as a binary outcome of low
risk versus at risk of VTE in this patient population. The model
had a negative predictive value of 99% across all of the
IMPROVE VTE scores, in line with previous VTE risk models in

100

90
80

Sensitivity

70

60
50

40

30
20

10

0
0

10

20

30

40

50

60

70

80

90

100

1– Specificity

Figure 2. Receiver operating characteristic curve for the validation cohort was 0.70.
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Risk Score

Positive Predictive
Value

Negative Predictive
Value

0 vs ≥1

0.0085

0.9987

0 to 1 vs ≥2

0.0107

0.9967

0 to 2 vs ≥3

0.0129

0.9958

0 to 3 vs ≥4

0.0151

0.9942

0 to 4 vs ≥5

0.0231

0.9940

0 to 5 vs ≥6

0.0284

0.9936

0 to 6 vs ≥7

0.0272

0.9932

0 to 7 vs ≥8

0.0250

0.9930

IMPROVE indicates International Medical Prevention Registry on Venous
Thromboembolism; RAM, risk assessment model.

this patient population.16 Moreover, the use of thromboprophylaxis did not appreciably change either the relative weight
or the rank order of the individual VTE risk factors, as was also
seen in the original IMROVE VTE score derivation study.17 The
7 independent clinical VTE risk factors of the IMPROVE VTE
risk score—previous VTE, known thrombophilia, lower limb
paralysis, cancer, immobilization ≥7 days, intensive care unit
or coronary care unit stay, and aged >60 years—have been
well described in previous studies in this patient population
and are simple to implement in a hospital setting.17
Multiple VTE RAMs in the medically ill population have
been derived mostly by expert consensus that included
subjective criteria.9,12,13,16 These models have been assessed
mostly in prospective management studies without proper
external validation.12,16 A recent validation study of 2 VTE
RAMs in this patient population used non–evidence-derived
RAMs.16 The IMPROVE RAM was also found to have good
calibration characteristics when applied to a large, global,
phase 3 study of thromboprophylaxis in hospitalized, acutely
ill medical patients, with an area under the ROC curve of
0.65.18 More recently, the IMPROVE VTE score has been
externally validated in another large-scale study in this patient
population and revealed good discrimination and calibration
characteristics.19 Based on a recent systematic review which
was performed using validated quality criteria for risk
modelling, only a few high quality evidence-derived VTE RAMs
exist which include the IMPROVE RAM and that of Woller
et al.10,11,20 The model by Woller et al incorporated a
validation cohort as part of the same population as the
derivation cohort, and this may have led to overly optimistic
discrimination characteristics.21 Proper validation of VTE
RAMs includes validation in external populations and additional impact analyses to demonstrate that the RAMs can be
used with reproducible accuracy and conﬁdence. The present
validation study of the IMPROVE RAM represents one of the
DOI: 10.1161/JAHA.114.001152

largest external, multicenter validation studies in this patient
population and demonstrates level 2 validation, which suggest
that the results can be used in various settings with
conﬁdence in their accuracy.14
Both the original derivation study and the present validation study of the IMPROVE RAM have important and
consistent clinical implications. With 8 million acutely ill
medical patients in the United States who are at risk of VTE,1
proper VTE risk assessment is important to ensure accurate
identiﬁcation of both at-risk patients and those patients who
may not beneﬁt from the bleeding risks associated with
pharmacological prophylaxis, estimated to be between 0.4%
and 1.7%.22 The present IMPROVE VTE validation study
suggests that at least two thirds of medical patients are at low
risk of VTE. Efforts to promote widespread pharmacological
thromboprophylaxis, as is currently suggested by national
quality organizations, without proper VTE risk assessment
may expose a large number of these patients to unnecessary
harm from bleeding and other adverse outcomes and to the
costs of pharmacological and mechanical VTE prophylaxis.6
The strengths of the present study include a large database
of electronic health records from 2 large acute-care hospitals
in a setting different from the original derivation cohort
population. In addition, standardized abstraction instruments
were used by trained personnel to extract the relevant
independent clinical risk factors in the validation population.
Moreover, the number of VTE events in both cases and
controls were sufﬁciently robust to allow assessment of both
the discrimination and the calibration of each VTE risk score
of the model. A limitation of the present study is its
retrospective design, which may have introduced bias in
terms of practice patterns by admission year and hospital.
This was minimized by ensuring that the control group was
adjusted both for hospital and year of admission. Another
limitation is the use of administrative database analysis based
on ICD-9 codes, which may lack speciﬁcity in identifying VTE
events; however, all VTE events were conﬁrmed by chart
review. There is a small possibility that some small number of
missing VTE events were overlooked, but given the strict
methodology of the abstraction process, this is unlikely and
would bias in favor of improved calibration over the original
derivation cohort. In addition, difﬁculties abstracting based on
administrative data may have resulted in unintended exclusion
of VTE events, although these conservative estimates were
based on strict methodology. This appears to be conﬁrmed by
the overall lower VTE risk, especially for those with higher
IMPROVE VTE risk scores, compared with the derivation
population; however this should not have inﬂuenced the
relative weights and estimates between risk scores. Furthermore, we acknowledge the difﬁculty of establishing immobility
criteria during the abstraction process, but we used electronic
nursing notes and physical therapy notes to specify immobilJournal of the American Heart Association
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Table 5. Predictive Values at Each Threshold of IMPROVE
RAM Score
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ity status at a patient-chart level. The present analysis
excluded patients who died during hospitalization; the original
analysis did not, which also may have affected overall study
estimates. Finally, the stroke population was not included in
the present validation study, compared with the derivation
cohort, because it was felt this group was sufﬁciently different
to warrant a separate validation study. This approach may
have contributed to the lower overall VTE risk seen in the
validation population compared with the derivation cohort.
To conclude, the present validation study of the IMPROVE
VTE RAM represents one of the largest, multicenter, external
validation studies to date of an evidence-derived and weighted
VTE RAM in the hospitalized, acutely ill medical patient
population. The IMPROVE RAM is able to incorporate 7 wellestablished and easy-to-implement clinical risk factors for VTE
in this patient population either at admission or during
hospital stay. The derivation and validation cohorts revealed
good discrimination and calibration for both the overall VTE
risk model and the identiﬁcation of at-risk patient groups. An
IMPROVE VTE risk score of ≤2, which encompassed more
than two thirds of the entire cohort, identiﬁed a population at
low risk of VTE that likely would not beneﬁt from pharmacological prophylaxis. This represents an important clinical
advance in the ﬁeld of VTE risk assessment in the hospitalized, acutely ill medical patient population by improving
assessment of at-risk VTE populations and avoiding unnecessary harm from overuse of prophylaxis. Additional prospective
management studies and impact analyses of the IMPROVE
VTE RAM should be undertaken in the acutely ill medical
patient group.

